The conflict centers on CME’s lawsuit against the CFTC and Chairman Michael Selig, which challenges the regulatory classification of perpetual futures. CME argues these products should be regulated as swaps under the Dodd-Frank Act rather than as standard futures. Outgoing CME CEO Terrence Duffy maintains that the regulator bypassed necessary rulemaking procedures, creating an uneven playing field for established firms.
Hyperliquid’s critique frames the dispute differently, suggesting the exchange is acting as a "petty monopolist" threatened by the first genuine innovation in U.S. derivatives in over a decade. Data from Better Markets reinforces this narrative, highlighting that CME’s near-total control of domestic exchange-traded derivatives leaves little room for alternative platforms. According to Chervinsky, the move is an "unforced error" that highlights a broader resistance to market evolution.

Comments (0)
No comments yet. Be the first!